Crystagen
Also known as: Peptídeo imunológico
Molecular Identifiers
Overview
Immune system bioregulatory tripeptide developed by the Khavinson group. Regulates gene expression in immune cells and supports thymus-independent immunity. Used in short cycles for immune modulation and strengthening.
The interest in Crystagen lies in immune modulation: regulation of gene expression in lymphocytes and NK cells, support for thymus-independent immunity, and normalization of cytokine production. It is proposed as an adjunct in recurrent infections, immunosenescence, and convalescence, without replacing specific therapy.
It has no approval as a medicine by the FDA, EMA, or ANVISA. It circulates mainly through compounding pharmacies and specialized suppliers of Russian-school peptides, in short cycles of 10-20 days repeated 2-4 times per year. It is often combined with Vilon in immunological bioregulation protocols.
It belongs to the family of short bioregulatory peptides developed by Vladimir Khavinson's group in St. Petersburg, derived from the fragmentation of thymic and bone marrow extracts. International clinical evidence is limited, concentrated in Russian-language literature and preclinical studies.
Within the Khavinson family, Crystagen sits in the thymus/immunity subgroup alongside Thymalin and Vilon: Thymalin is the "ancestor" derived from thymic extract, Vilon is the short dipeptide (Lys-Glu), and Crystagen is the tripeptide (Glu-Asp-Pro), described with a focus on thymus-independent immunity. All of this comparative literature is largely Russian and preclinical.
EDP Glu-Asp-Pro Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in immune cells
- Support for thymus-independent immunity
- Modulation of lymphocyte and NK cell activity
- Normalization of cytokine production
- Bioregulatory effect on innate and adaptive immune system
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) |
| Frequency | 1-2 times daily, before meals |
| Timing | Before meals |
| Duration | 1 month per cycle, repeat the course every 3-6 months |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Crystagen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Crystagen.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily